Jazz Pharmaceuticals Plc(NASDAQ) JAZZ

Jazz Pharmaceuticals helps people with rare diseases like sleep disorders and cancer. It makes specialized medicines that improve the lives of patients with few other choices. The company sells these treatments to doctors and hospitals around the world.

What is in the Medicine Cabinet?

• Sleep Medicines: Specialized treatments for narcolepsy and idiopathic hypersomnia, a condition causing extreme daytime sleepiness; Xywav accounted for 41% of net product sales in 2025.
• Rare Epilepsy: Oral solutions used to treat seizures from severe childhood-onset conditions; Epidiolex generated 26% of net product sales in 2025.
• Oncology Treatments: Targeted therapies for lung, brain, and bile duct cancers; Rylaze and Zepzelca accounted for 10% and 8% of net product sales in 2025, respectively.
• Hematology Products: Solutions for rare blood disorders and complications from stem cell transplants; includes the medicine Defitelio.

Expanding the Portfolio

• Acquired Chimerix in April 2025 to add Modeyso, a treatment for aggressive brain tumors, to the oncology pipeline.
• Formed a partnership with Zymeworks in 2022 to develop and sell zanidatamab for specific types of cancer.
• Licensed new cancer-fighting molecules from Redx and Werewolf to expand early-stage research activities.
• Launched Ziihera in December 2024 following an accelerated approval from the U.S. Food and Drug Administration.

What Makes the Business Stand Out

The company maintains a specialized distribution network where certain sleep medicines are shipped directly to patients through a single central pharmacy to ensure safety. It also operates its own manufacturing facilities in Ireland, the United Kingdom, and Italy to keep tight control over the production of its rare disease therapies.

The Recent Numbers

• Total revenue reached $1.2 billion in Q4 2025, a 10.1% increase compared to the previous year.
• Operating income rose to $909.2 million in Q4 2025, up 376.6% from Q4 2024.
• Net income for Q4 2025 was $203.5 million, representing a 6.5% gain over the same period in 2024.
• Free cash flow was $296.8 million in Q4 2025, down 23% from $385.3 million in Q4 2024.

Bottom Line

Jazz Pharmaceuticals has moved from relying on a single sleep drug to managing a diverse portfolio of neuroscience and oncology treatments. This shift toward multiple high-need therapies has helped the company grow its revenue while reaching more patients globally.